Brimonidine Intravitreal Implant for Dry AMD: Allergan


Allergan is conducting a Phase II clinical trial of brimonidine tartrate, delivered through an intravitreal implant, for the treatment of dry age-related macular degeneration (AMD). The international study includes approximately 100 participants. Two different doses of the drug are being evaluated. Known as the posterior segment drug delivery system, the intravitreal implant provides sustained delivery of the drug to the back of the eye. Brimonidine is a drug approved by the FDA for the treatment of glaucoma. In prior clinical and preclinical evaluations, the drug showed potential for slowing vision loss from various retinal degenerations.

Trial Status:
Ongoing, not recruiting.


Glaucoma drug brimonidine moving into clinical trials for RP, AMD

Additional Information:
Brimonidine clinical trial for dry AMD listing on